The Director General of the world health organization tedros adhanom Ghebreyesus called "scientific breakthrough" results of clinical trials in the UK steroid dexamethasone for the treatment of COVID-19.
As revealed in the Oxford study, anti-inflammatory drug dexamethasone reduces the risk of death in patients with COVID-19, connected to the ventilator, 35% among patients receiving oxygen at 20%. The drug in Britain costs about five pounds (437 rubles – approx. ed.). The British government on Tuesday has approved dexamethasone for the treatment of COVID-19.
"This is the first drug that showed a decrease in the level of mortality among patients with COVID-19, which require oxygen therapy or mechanical ventilation, " – leads the organization’s statement of the General Director.
Of ghebreyesus called the test results "good news".
Who said that the UK has provided organizations the preliminary results of the study. "We look forward to full data analysis in the coming days", – added in the organization.
In Russia for the treatment COVID-19 was previously approved by the drug "Aviewer" on database "Favipiravir". It has proved effective in clinical trials. In may, the drug was registered by the Ministry of health. While it is impossible to buy at the pharmacy, it is available only to hospital patients and used under medical supervision.
